Two Distinct Pathways Mediated by PA28 and hsp90 in Major Histocompatibility Complex Class I Antigen Processing

Taketoshi Yamano(Nagasaki University), Shigeo Murata(Tokyo Metropolitan Institute of Medical Science), Naoki Shimbara, Noriaki Tanaka(Okayama University), Tomoki Chiba(Tokyo Metropolitan Institute of Medical Science), Keiji Tanaka(Tokyo Metropolitan Institute of Medical Science), Katsuyuki Yui(Nagasaki University), Heiichiro Udono(Nagasaki University)
The Journal of Experimental Medicine
July 8, 2002
Cited by 73Open Access
Full Text

Abstract

Major histocompatibility complex (MHC) class I ligands are mainly produced by the proteasome. Herein, we show that the processing of antigens is regulated by two distinct pathways, one requiring PA28 and the other hsp90. Both hsp90 and PA28 enhanced the antigen processing of ovalbumin (OVA). Geldanamycin, an inhibitor of hsp90, almost completely suppressed OVA antigen presentation in PA28α−/−/β−/− lipopolysaccharide blasts, but not in wild-type cells, indicating that hsp90 compensates for the loss of PA28 and is essential in the PA28-independent pathway. In contrast, treatment of cells with interferon (IFN)-γ, which induces PA28 expression, abrogated the requirement of hsp90, suggesting that IFN-γ enhances the PA28-dependent pathway, whereas it diminishes hsp90-dependent pathway. Importantly, IFN-γ did not induce MHC class I expressions in PA28-deficient cells, indicating a prominent role for PA28 in IFN-γ–stimulated peptide supply. Thus, these two pathways operate either redundantly or specifically, depending on antigen species and cell type.


Related Papers

No related papers found

Powered by citation graph analysis